Sun Pharma's SCD-044 Fails to Meet Primary Endpoints in Phase 2 Clinical Trials for Psoriasis and Atopic Dermatitis

Sun Pharmaceutical Industries Limited announced top-line results from the Phase 2 clinical trials evaluating SCD-044 for moderate to severe psoriasis and atopic dermatitis. The study did not meet its primary endpoint of 75% improvement in PASI score at Week 16 for psoriasis, and the primary objective of 75% improvement in EASI score at Week 16 for atopic dermatitis. There were no major safety or tolerability concerns with SCD-044. Sun Pharma is discontinuing clinical trials of the asset and has no further plans for development of SCD-044.